Mirati Therapeutics Shares Outstanding 2006-2021 | MRTX

Mirati Therapeutics shares outstanding history from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Mirati Therapeutics shares outstanding for the quarter ending June 30, 2021 were 0.051B, a 17.45% increase year-over-year.
  • Mirati Therapeutics 2020 shares outstanding were 0.045B, a 20.07% increase from 2019.
  • Mirati Therapeutics 2019 shares outstanding were 0.037B, a 21.26% increase from 2018.
  • Mirati Therapeutics 2018 shares outstanding were 0.031B, a 22.17% increase from 2017.
Mirati Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 45
2019 37
2018 31
2017 25
2016 20
2015 17
2014 13
2013 11
2012 7
2011 0
2010
2009
2008
2007
2006
2005
Mirati Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 51
2021-03-31 51
2020-12-31 45
2020-09-30 45
2020-06-30 44
2020-03-31 43
2019-12-31 37
2019-09-30 39
2019-06-30 36
2019-03-31 35
2018-12-31 31
2018-09-30 32
2018-06-30 30
2018-03-31 29
2017-12-31 25
2017-09-30 25
2017-06-30 25
2017-03-31 24
2016-12-31 20
2016-09-30 20
2016-06-30 20
2016-03-31 19
2015-12-31 17
2015-09-30 17
2015-06-30 16
2015-03-31 15
2014-12-31 13
2014-09-30 15
2014-06-30 13
2014-03-31 13
2013-12-31 11
2013-09-30 10
2013-06-30 10
2013-03-31 10
2012-12-31 8
2012-09-30 6
2012-06-30 6
2012-03-31 6
2011-12-31 7
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
2008-12-31
2008-09-30
2008-06-30
2008-03-31
2007-12-31
2007-09-30
2007-06-30
2007-03-31
2006-12-31
2006-09-30
2006-06-30
2006-03-31
2005-12-31
2005-09-30
2005-06-30
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $8.588B $0.013B
Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29